ZYUS Life Sciences Corporation ZYUS

ZYUS Life Sciences Corporation (the "Company" and or "ZYUS") (TSXV: ZYUS), a clinical-stage life sciences company focused on the development and commercialization of novel non-opioid drug candidates for pain management, today announced positive topline results from its Phase 2a UTOPIA-1 (Unique Treatment of Oncology Pain in Advanced Cancer) clinical trial evaluating dosing, safety, and efficacy of Trichomylin® softgel capsules in patients with advanced cancer experiencing moderate to severe canc

ZYUS Life Sciences Corporation (the "ZYUS" and or "Company") (TSXV: ZYUS), a clinical-stage life sciences company focused on the development and commercialization of novel drug product candidates for chronic pain is pleased to announce that it anticipates announcing topline results from its Phase 2a UTOPIA-1 clinical trial on September 30, 2026. In addition, the Company is pleased to announce the results of its Annual General and Special Meeting of Shareholders (the "Meeting") held on September

ZYUS Life Sciences Corporation (the "ZYUS" or "Company") (TSXV: ZYUS), a clinical-stage life sciences company focused on the development and commercialization of novel drug product candidates for chronic pain, today provided a general business update and announced changes in executive leadership, effective September 14, 2026. As part of this business update, trading in the Company's common shares (the "Shares") on the TSX Venture Exchange (the "TSXV") commenced at market open on September 14, 20

ZYUS Life Sciences Corporation ("ZYUS" and or the "Company") (TSXV: ZYUS), a clinical-stage life sciences company focused on the development and commercialization of novel non-opioid drug candidates for pain management, today provides an update regarding its liquidity position, working capital, certain outstanding financial obligations and the measures being undertaken by the Company to strengthen its financial position and address its working capital deficiency, and announces its reinstatement

ZYUS Life Sciences Corporation (the "Company") (TSXV: ZYUS), a clinical-stage life sciences company focused on the development and commercialization of novel non-opioid drug candidates for pain management, is pleased to announce that its wholly-owned subsidiary, ZYUS Life Sciences Inc. ("ZYUS Inc."), has completed its secured loan financing (the "Secured Loan"). The Secured Loan was completed with certain lenders (the "Lenders"), including insiders of the Company, in nine tranches for aggregate

ZYUS Life Sciences Corporation (the "Company") (TSXV: ZYUS), a clinical-stage life sciences company focused on the development and commercialization of novel non-opioid drug candidates for pain management, is pleased to announce that its wholly-owned subsidiary, ZYUS Life Sciences Inc. ("ZYUS Inc."), has closed a ninth tranche (the "Ninth Tranche") of a secured loan financing (the "Secured Loan") on August 18, 2026 with certain lenders (the "Lenders"), one of whom is an insider of the Company, f

ZYUS Life Sciences Corporation (the "Company") (TSXV: ZYUS), a clinical-stage life sciences company focused on the development and commercialization of novel non-opioid drug candidates for pain management, is pleased to announce that its wholly-owned subsidiary, ZYUS Life Sciences Inc. ("ZYUS Inc."), has closed an eighth tranche (the "Eighth Tranche") of a secured loan financing (the "Secured Loan") on August 13, 2026 with certain lenders (the "Lenders"), including certain insiders of the Compan

ZYUS Life Sciences Corporation (the "Company") (TSXV: ZYUS), a clinical-stage life sciences company focused on the development and commercialization of novel non-opioid drug candidates for pain management, is pleased to announce that its wholly-owned subsidiary, ZYUS Life Sciences Inc. ("ZYUS Inc."), has closed a seventh tranche (the "Seventh Tranche") of a secured loan financing (the "Secured Loan") on July 29, 2026 with certain lenders (the "Lenders"), including an insider of the Company, for

ZYUS Life Sciences Corporation (the "Company") (TSXV: ZYUS), a clinical-stage life sciences company focused on the development and commercialization of novel non-opioid drug candidates for pain management, announces a strategic realignment of its corporate structure and leadership to strengthen its focus on the Company's core clinical development priorities.